HINDUSTAN BIO SCIENCES LTD.

Hindustan Bio Sciences Ltd has announced its 34th Annual General Meeting (AGM) for the financial year 2025-26. The meeting is scheduled for September 30, 2026, at the company's registered office. Key agenda items include the adoption of the audited standalone financial statements for the fiscal year ending March 31, 2026, the re-appointment of Smt. Uma Jampana as a director, and a special resolution to consider and approve a scheme for the reduction of the company's share capital. The proposed reduction aims to decrease the paid-up share capital from ₹2,05,01,600 to ₹92,25,720.

Hindustan Bio Sciences Ltd has submitted its 34th Annual Report, including the notice for its Annual General Meeting (AGM) for the financial year 2025-26. The AGM is scheduled for September 30, 2026, at 10:00 AM. Key agenda items include the adoption of audited standalone financial statements for FY26, the re-appointment of Smt. Uma Jampana as a director, and consideration of a scheme for the reduction of the company's share capital. The proposed reduction aims to decrease the paid-up share capital from ₹2,05,01,600 to ₹92,25,720, subject to NCLT approval.

Hindustan Bio Sciences Limited's Board of Directors has approved a Scheme of Reduction of Capital. This involves cancelling 56,37,940 equity shares of ₹2 each, reducing the paid-up equity share capital from ₹2,05,01,600 to ₹92,25,720. The company aims to set off accumulated losses of ₹1,12,75,880 against the reduced capital. Following this, the face value of shares will be consolidated from ₹2 to ₹10, with every 5 shares of ₹2 consolidating into 1 share of ₹10. Shareholders will receive 9 shares of ₹10 for every 100 shares of ₹2 held. The proposal requires shareholder and NCLT approval.

Hindustan Bio Sciences Ltd has announced a Board of Directors meeting scheduled for August 31, 2026. The primary agenda items include considering a revised notice for the 34th Annual General Meeting (AGM) and approving a Draft Scheme of Reorganization/Rearrangement of Share Capital. Additionally, the company has implemented a trading window closure for its securities from August 27, 2026, until 48 hours after the meeting's conclusion, affecting all connected persons, insiders, and their immediate relatives, in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015.

Hindustan Bio Sciences Ltd announced its un-audited standalone financial results for the first quarter ended June 30, 2026. The Board of Directors approved these results along with the Limited Review Report from the statutory auditors. Additionally, the Board approved the notice for the 34th Annual General Meeting (AGM), scheduled for September 30, 2026, along with the Directors' and Corporate Governance Reports for the financial year ended March 31, 2026. Mr. VBSS Prasad was appointed as Scrutinizer for the AGM's e-voting process.

Hindustan Bio Sciences Ltd announced the outcome of its Board Meeting held on July 31, 2026. The board approved the un-audited standalone financial results for the first quarter ended June 30, 2026, along with the limited review report. Additionally, the notice for the 34th Annual General Meeting (AGM), scheduled for September 30, 2026, was approved, along with the Directors' Report and Corporate Governance Report for the financial year ended March 31, 2026. Mr. VBSS Prasad was appointed as Scrutinizer for the AGM's voting process.

Hindustan Bio Sciences Ltd has announced that its Board of Directors will convene on July 31, 2026. The primary agenda for this meeting is to consider and approve the un-audited financial results for the quarter ended June 30, 2026. The meeting will be held at the company's registered office in Banjara Hills, Hyderabad. Other matters may also be discussed with the permission of the Chair.

Hindustan Bio Sciences Ltd has announced the closure of its trading window for dealing in the company's securities. The window will be shut from July 01, 2026, until 48 hours after the announcement of the Standalone Un-Audited Financial Results for the quarter ending June 30, 2026. This closure is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's internal codes. The company has also ensured the freezing of PANs for designated persons and their immediate relatives during this period. The date for the Board Meeting to declare these financial results will be communicated separately.

Hindustan Bio Sciences Ltd's board approved the audited standalone financial results for the fourth quarter and financial year ended March 31, 2026. The company reported revenue from operations of ₹73.71 Cr for the year ended March 31, 2026, compared to ₹81.33 Cr in the previous year. The board also approved the appointment of Mr. GBK Viswanadham as an Internal Auditor for the financial year 2026-27.

Hindustan Bio Sciences Ltd's board meeting on May 30, 2026, approved the appointment of Mr. GBK Viswanadham as the Internal Auditor for the financial year 2026-27, based on the Audit Committee's recommendations. The board also approved the audited standalone financial results for Q4 and the financial year ended March 31, 2026, along with the audit report. The meeting commenced at 02:00 P.M. and concluded at 3:00 P.M.